As part of our ongoing aim to bring you reports of new developments, we have added a review of a recent study ECHELON-1: brentuximab vedotin with chemotherapy as first line treatment for stage III or IV Hodgkin Lymphoma.
Independent commentary for the review has been provided by Dr Michael Gilbertson, clinical and laboratory haematologist at Monash Health and Western Health.
Please login below to download this issue (PDF)